A Phase 3 interventional study of nivolumab and ipilimumab in Non-Small Cell Lung Cancer (NSCLC), sponsored by Bristol-Myers Squibb. Completed at 183 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-24.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 9 that started in 2019, is one of 24 in phase 3, and was the 78th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
EuroCityClinic LLC · Sites in Russia
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 78 · Phase 3 24 · Phase 4 2
First in 2006; this study’s year is marked. 9 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 925 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 120 interventional studies. Of the 62 that completed or were terminated, 44 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 120 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb: 21 open now, 35 under way, 10 of them phase 3. Of 91 finished, 47 (52%) have results posted.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 6th largest by enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2019, is one of 27 in phase 3, and was the 74th registered.
Bristol-Myers Squibb’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
13 of the studies testing nivolumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02595944Phase 3National Cancer Institute (NCI)Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | 2027-05-31 |
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT05597800Universita di VeronaNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT06275360VA Office of Research and DevelopmentRepositioning Immunotherapy in VetArans With Lung Cancer | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Bristol-Myers Squibb’s 131 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Concurrent chemoradiotherapy (CCRT)
Biological: nivolumab · Biological: ipilimumab
Concurrent chemoradiotherapy (CCRT)
Biological: nivolumab
Concurrent chemoradiotherapy (CCRT)
Biological: durvalumab
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)
Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 53 months)
Overall Survival (OS)
Overall Survival (OS) for all randomized participants is the time between randomization and the date of death from any cause based on Kaplan-Meier estimates. For participants who are alive, their survival time was censored at the last date that they were known to be alive. OS was censored for participants at the date of randomization if they had no follow-up.
Time frame: From randomization untill death (up to approximately 61 months)
Arm B Vs Arm C and Arm A Vs Arm B- Progression-Free Survival (Irrespective of Subsequent Therapy) by RECIST 1.1 Per Blinded Independent Central Review (BICR)
Progression-Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Objective Response Rate (ORR) by BICR
Objective Response Rate (ORR) is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Duration of Response (DoR) by RECIST 1.1 Per BICR
Duration of objective response (DoR) is defined as the time between the date of first confirmed response (CR or PR) to the date of the first documented tumor progression (per RECIST 1.1) per BICR assessment, or death due to any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Time to Response (TTR) by RECIST 1.1 Per BICR
Time to response (TTR) is defined as the time, in months, from randomization to the first objective documentation of PR or better assessed per BICR. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.
Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Progression Free Survival (PFS) by RECIST 1.1 Per Investigator Assessment
Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on Investigator assessments (per RECIST v1.1), or death due to any cause, whichever occurs first Calculated using Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Objective Response Rate (ORR) by RECIST 1.1 Per Investigator Assessment
ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by investigator assessment per response evaluation criteria in solid tumors (RECIST) v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Duration of Response (DOR) by RECIST 1.1 Per Investigator Assessment
Duration of objective response (DoR) is defined as the time between the date of first confirmed response (CR or PR) to the date of the first documented tumor progression (per RECIST 1.1) per investigator assessment, or death due to any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Time to Response (TTR) by RECIST 1.1 Per Investigator Assessment
Time to response (TTR) is defined as the time, in months, from randomization to the first objective documentation of PR or better assessed per investigator assessment. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Time to Death or Distant Metastases (TDDM)
Time to Death or Distant Metastases (TDDM) is defined as the time from the date of randomization until the first date of distant metastasis or death in the absence of distant metastasis based on Kaplan-Meier estimates. Distant metastasis is defined as any new lesion that is outside of the thorax (except for heart) according to RECIST 1.1, as assessed by the Investigator.
Time frame: From randomization until metastases or death, whichever occurs first (up to approximately 61 months)
Number of Participants With Adverse Events (AEs), Serious AEs and Select AEs
An Adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product. A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose (Day 1) till 30 days after the last dose (up to approximately 19 months)
Change From Baseline in Non-small Cell Lung Cancer (NSCLC)-Symptom Assessment Questionnaire (SAQ) Total Score at Week 48
The NSCLC-SAQ is a questionnaire used in clinical trials to understand how non-small cell lung cancer (NSCLC) affects your daily life and well-being. It has 7 questions that ask about your symptoms over the past 7 days, including cough, pain, shortness of breath, fatigue, and appetite loss. The total scores from the questionnaire range from 0 to 20. A higher score means you have more severe symptoms and are feeling worse, which is a bad outcome. A lower score means you have fewer symptoms and are feeling better, which is a good outcome.
Time frame: Baseline (Day 1) and Week 48
| Milestone | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| Started | 287 | 320 | 318 |
| Completed | 103 | 138 | 144 |
| Not completed | 184 | 182 | 174 |
Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Arm A:Nivo + CCRT/Nivo + Ipi | Arm C: CCRT/Durva |
|---|---|---|
| Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR) | 16.69 (12.58 to 21.98) | 15.64 (13.67 to 19.75) |
Overall Survival (OS) for all randomized participants is the time between randomization and the date of death from any cause based on Kaplan-Meier estimates. For participants who are alive, their survival time was censored at the last date that they were known to be alive. OS was censored for participants at the date of randomization if they had no follow-up.
| months | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| Overall Survival (OS) | 34.60 (26.81 to NA) | 39.49 (33.48 to NA) | 39.79 (30.92 to NA) |
Progression-Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| Arm B Vs Arm C and Arm A Vs Arm B- Progression-Free Survival (Irrespective of Subsequent Therapy) by RECIST 1.1 Per Blinded Independent Central Review (BICR) | 16.82 (12.58 to 22.05) | 17.38 (14.09 to 22.14) | 15.67 (13.77 to 20.83) |
Objective Response Rate (ORR) is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| percentage of participants | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| Objective Response Rate (ORR) by BICR | 67.6 (61.8 to 73.0) | 72.2 (66.9 to 77.0) | 64.5 (58.9 to 69.7) |
Duration of objective response (DoR) is defined as the time between the date of first confirmed response (CR or PR) to the date of the first documented tumor progression (per RECIST 1.1) per BICR assessment, or death due to any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| Duration of Response (DoR) by RECIST 1.1 Per BICR | 25.76 (2.1 to 47.9) | 31.84 (1.6 to 44.3) | 25.17 (1.0 to 44.3) |
Time to response (TTR) is defined as the time, in months, from randomization to the first objective documentation of PR or better assessed per BICR. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.
| months | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| Time to Response (TTR) by RECIST 1.1 Per BICR | 2.92 (0.9 to 22.2) | 2.96 (1.3 to 41.9) | 2.92 (1.2 to 24.9) |
Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on Investigator assessments (per RECIST v1.1), or death due to any cause, whichever occurs first Calculated using Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| Progression Free Survival (PFS) by RECIST 1.1 Per Investigator Assessment | 16.82 (13.83 to 20.40) | 17.71 (13.83 to 24.71) | 16.53 (13.77 to 19.38) |
ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by investigator assessment per response evaluation criteria in solid tumors (RECIST) v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| percentage of participants | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| Objective Response Rate (ORR) by RECIST 1.1 Per Investigator Assessment | 61.3 (55.4 to 67.0) | 63.1 (57.6 to 68.4) | 57.9 (52.2 to 63.4) |
Duration of objective response (DoR) is defined as the time between the date of first confirmed response (CR or PR) to the date of the first documented tumor progression (per RECIST 1.1) per investigator assessment, or death due to any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| Duration of Response (DOR) by RECIST 1.1 Per Investigator Assessment | 22.83 (0.0 to 47.4) | 33.18 (0.0 to 47.6) | 27.93 (0.0 to 46.5) |
Time to response (TTR) is defined as the time, in months, from randomization to the first objective documentation of PR or better assessed per investigator assessment. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| Time to Response (TTR) by RECIST 1.1 Per Investigator Assessment | 2.96 (1.9 to 25.2) | 2.92 (1.9 to 16.5) | 2.89 (1.4 to 22.1) |
Time to Death or Distant Metastases (TDDM) is defined as the time from the date of randomization until the first date of distant metastasis or death in the absence of distant metastasis based on Kaplan-Meier estimates. Distant metastasis is defined as any new lesion that is outside of the thorax (except for heart) according to RECIST 1.1, as assessed by the Investigator.
| months | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| Time to Death or Distant Metastases (TDDM) | 30.65 (22.57 to NA) | 36.14 (25.86 to NA) | 30.36 (21.62 to 40.15) |
An Adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product. A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| ADVERSE EVENTS | 279 | 315 | 312 |
| SERIOUS ADVERSE EVENTS | 155 | 156 | 136 |
| GASTROINTESTINAL ADVERSE EVENT | 67 | 60 | 54 |
| HEPATIC ADVERSE EVENT | 55 | 59 | 72 |
| PULMONARY ADVERSE EVENT | 87 | 92 | 55 |
| RENAL ADVERSE EVENT | 25 | 16 | 32 |
| SKIN ADVERSE EVENT | 111 | 115 | 115 |
| HYPERSENSITIVITY/INFUSION REACTION | 18 | 17 | 9 |
The NSCLC-SAQ is a questionnaire used in clinical trials to understand how non-small cell lung cancer (NSCLC) affects your daily life and well-being. It has 7 questions that ask about your symptoms over the past 7 days, including cough, pain, shortness of breath, fatigue, and appetite loss. The total scores from the questionnaire range from 0 to 20. A higher score means you have more severe symptoms and are feeling worse, which is a bad outcome. A lower score means you have fewer symptoms and are feeling better, which is a good outcome.
| Score on a Scale | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| Change From Baseline in Non-small Cell Lung Cancer (NSCLC)-Symptom Assessment Questionnaire (SAQ) Total Score at Week 48 | -0.60 ± 3.260 | -0.91 ± 3.507 | -0.89 ± 3.731 |
Collected over All-cause mortality was collected from randomization until death due to any cause (up to approximately 61 months). Serious and Non-serious AEs were collected from first dose (Day 1) till 30 days after the last dose (up to approximately 19 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A:Nivo + CCRT/Nivo + Ipi | 132/287 (46%) | 180/282 (63.8%) | 273/282 (96.8%) |
| Arm B: Nivo + CCRT/Nivo | 132/320 (41.3%) | 181/318 (56.9%) | 310/318 (97.5%) |
| Arm C: CCRT/Durva | 132/318 (41.5%) | 145/317 (45.7%) | 307/317 (96.8%) |
| Event | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| PneumoniaInfections and infestations | 33/282 | 39/318 | 29/317 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 32/282 | 32/318 | 11/317 |
| Radiation pneumonitisInjury, poisoning and procedural complications | 18/282 | 15/318 | 13/317 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 17/282 | 12/318 | 14/317 |
| Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders | 13/282 | 10/318 | 2/317 |
| COVID-19Infections and infestations | 9/282 | 11/318 | 6/317 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/282 | 9/318 | 4/317 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 4/282 | 5/318 | 10/317 |
| AnaemiaBlood and lymphatic system disorders | 6/282 | 3/318 | 9/317 |
| OesophagitisGastrointestinal disorders | 1/282 | 8/318 | 4/317 |
| Event | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 124/282 | 132/318 | 134/317 |
| NauseaGastrointestinal disorders | 98/282 | 104/318 | 108/317 |
| ConstipationGastrointestinal disorders | 82/282 | 78/318 | 89/317 |
| CoughRespiratory, thoracic and mediastinal disorders | 82/282 | 83/318 | 87/317 |
| Decreased appetiteMetabolism and nutrition disorders | 79/282 | 64/318 | 77/317 |
| OesophagitisGastrointestinal disorders | 74/282 | 81/318 | 69/317 |
| FatigueGeneral disorders | 60/282 | 61/318 | 77/317 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 62/282 | 76/318 | 48/317 |
| White blood cell count decreasedInvestigations | 65/282 | 73/318 | 63/317 |
| PruritusSkin and subcutaneous tissue disorders | 65/282 | 54/318 | 51/317 |
| Age, Continuous(years) | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva | Total |
|---|---|---|---|---|
| Mean | 63.7 ± 8.99 | 63.7 ± 8.50 | 63.9 ± 9.18 | 63.8 ± 8.88 |
| Sex: Female, Male(Participants) | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva | Total |
|---|---|---|---|---|
| Female | 67 | 76 | 79 | 222 |
| Male | 220 | 244 | 239 | 703 |
| Ethnicity (NIH/OMB)(Participants) | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva | Total |
|---|---|---|---|---|
| Hispanic or Latino | 28 | 32 | 32 | 92 |
| Not Hispanic or Latino | 155 | 167 | 157 | 479 |
| Unknown or Not Reported | 104 | 121 | 129 | 354 |
| Race (NIH/OMB)(Participants) | Arm A:Nivo + CCRT/Nivo + Ipi | Arm B: Nivo + CCRT/Nivo | Arm C: CCRT/Durva | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 93 | 119 | 105 | 317 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 4 | 2 | 11 |
| White | 182 | 192 | 204 | 578 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 5 | 7 | 18 |
Showing the first 100 of 183 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2019 to primary completion in Mar 2024, 53 months.
Results were first posted in Jul 2025, 1 year 4 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 53 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab
Carcinoma, Non-Small-Cell Lung →